{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T20:42:20Z","timestamp":1771015340171,"version":"3.50.1"},"reference-count":13,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.bmj.com\/company\/legal-information\/terms-conditions\/legal-information\/tdm-licencepolicy"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2018,11,22]]},"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:p>Olmesartan-associated enteropathy (OAE) is increasingly being recognised as a major differential diagnosis in patients with villous atrophy and negative coeliac disease (CD) serology. OAE and positive coeliac markers have rarely been reported. We report a case of diarrhoea and small bowel villous blunting associated with a transient elevation of antitissue transglutaminase antibody (ATTG). On discontinuation of olmesartan, symptoms improved, repeat biopsies were normal and levels of ATTG also returned normal. We discuss a possible explanation for the transient elevation in ATTG and the significance of considering OAE\/CD overlap.<\/jats:p>","DOI":"10.1136\/bcr-2018-225518","type":"journal-article","created":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T17:19:47Z","timestamp":1545153587000},"page":"e225518","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Case of olmesartan-associated enteropathy and transient positive antitissue transglutaminase serology"],"prefix":"10.1136","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7003-1131","authenticated-orcid":false,"given":"Jenan","family":"Ghaith","sequence":"first","affiliation":[{"name":"Internal Medicine Residency Program, University of McGill, Montreal, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ismail A","family":"Raslan","sequence":"additional","affiliation":[{"name":"Internal Medicine Residency Program, University of McGill, Montreal, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Szilagyi","sequence":"additional","affiliation":[{"name":"Medicine Division of Gastroenterology, Sir Mortimer B Davis Jewish General Hospital, Montreal, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mona","family":"Alameldin","sequence":"additional","affiliation":[{"name":"Department of Pathology, Sir Mortimer B Davis Jewish General Hospital, Montreal, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2018,12,13]]},"reference":[{"key":"2025082711444605000_11.1.e225518.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2012.10.005"},{"key":"2025082711444605000_11.1.e225518.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2012.06.003"},{"key":"2025082711444605000_11.1.e225518.3","unstructured":"FDA. FDA Drug Safety Communication: FDA approves label changes to include intestinal problems (sprue-like enteropathy) linked to blood pressure medicine olmesartan medoxomi [Internet]: U.S. Department of Health and Human Services, 2013. cited 15 Mar 2018. https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm359477.htm."},{"key":"2025082711444605000_11.1.e225518.4","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jpge.2015.10.007","article-title":"Enteropathy Associated with Olmesartan","volume":"23","author":"Silva","year":"2016","journal-title":"GE Port J Gastroenterol"},{"key":"2025082711444605000_11.1.e225518.5","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1111\/apt.14518","article-title":"Use of olmesartan and enteropathy outcomes: a multi-database study","volume":"47","author":"Dong","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"2025082711444605000_11.1.e225518.6","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1038\/ajg.2015.291","article-title":"Could HLA-DQ suggest why some patients have olmesartan -related diarrhea and others don\u2019t?","volume":"110","author":"Marco-Marqu\u00e9s","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"2025082711444605000_11.1.e225518.7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0125024","article-title":"Gastrointestinal disorder associated with olmesartan mimics autoimmune enteropathy","volume":"10","author":"Scialom","year":"2015","journal-title":"PLoS One"},{"key":"2025082711444605000_11.1.e225518.8","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.dld.2015.09.014","article-title":"Potential coeliac disease markers and autoimmunity in olmesartan induced enteropathy: A population-based study","volume":"48","author":"Esteve","year":"2016","journal-title":"Dig Liver Dis"},{"key":"2025082711444605000_11.1.e225518.9","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.5858\/arpa.2015-0204-RA","article-title":"Olmesartan-associated enteropathy: A review of clinical and histologic findings","volume":"139","author":"Choi","year":"2015","journal-title":"Arch Pathol Lab Med"},{"key":"2025082711444605000_11.1.e225518.10","doi-asserted-by":"publisher","DOI":"10.1159\/000370205"},{"key":"2025082711444605000_11.1.e225518.11","unstructured":"Rostom A , Dub\u00e9 C , Cranney A , et al . Celiac disease: Summary. Agency for Healthcare Research and Quality 2004."},{"key":"2025082711444605000_11.1.e225518.12","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0b013e31816200e5"},{"key":"2025082711444605000_11.1.e225518.13","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.3390\/nu9101050","article-title":"Intestinal production of anti-tissue transglutaminase 2 antibodies in patients with diagnosis other than celiac disease","volume":"9","author":"Maglio","year":"2017","journal-title":"Nutrients"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/data.bmj.org\/tdm\/10.1136\/bcr-2018-225518","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2018-225518","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T18:44:53Z","timestamp":1756320293000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2018-225518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":13,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12,13]]},"published-print":{"date-parts":[[2018,11]]}},"alternative-id":["10.1136\/bcr-2018-225518"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2018-225518","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11]]}}}